BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...at BMO Capital Markets, where he was a senior equity research analyst covering biopharma companies. Goodwin...
...life sciences practices as a partner in the law firm’s New York office. Wound joined Goodwin...
BioCentury | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

...and business development at Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN). Wendy Pan told BioCentury she joined Goodwin...
...Inc. (NASDAQ:AMGN) acquired in 2014. BioCentury Staff Arch Oncology Inc. Cerevel Therapeutics LLC Intellia Therapeutics Inc. Medeor Therapeutics Inc. RedHill Biopharma Ltd. Goodwin...
BioCentury | Dec 21, 2018
Company News

CFIUS gives Novartis, Endocyte deal a pass -- for now

...CFIUS left the door open to potentially revisiting the deal down the road, according to Goodwin...
BioCentury | Dec 19, 2018
Company News

CFIUS gives Novartis, Endocyte deal a pass -- for now

...CFIUS left the door open to potentially revisiting the deal down the road, according to Goodwin...
BioCentury | Dec 17, 2018
Politics & Policy

ACA ruling threatens biosimilars provisions

...entire law as an unconstitutional overreach. An appeal is likely. Elaine Blais, a partner at Goodwin...
BioCentury | Oct 25, 2018
Distillery Therapeutics

Infectious disease

...New York, N.Y. email: elizabeth.campbell@rockefeller.edu CONTACT: Sean F. Brady, same affiliation as above email: sbrady@rockefeller.edu Amy Goodwin Rockefeller...
BioCentury | Oct 19, 2018
Politics, Policy & Law

CFIUS waiting game

...is emerging biotech.” Stephen Paul Mahinka, Morgan Lewis According to two attorneys, Richard Matheny at Goodwin...
...“The costs for preparing a notice or a declaration would not be trivial.” Richard Matheny, Goodwin...
BioCentury | Oct 18, 2018
Distillery Therapeutics

Cancer

...Medicine, Stanford, Calif. email: suzanakahn@gmail.com CONTACT: Samuel H. Cheshier, same affiliation as above email: samuel.chesire@hsc.utah.edu Amy Goodwin Stanford...
BioCentury | Apr 18, 2018
Politics & Policy

Patients emphasize unmet needs in opioid use disorder meeting

...FDA is accepting public comments on the PFDD for opioid use disorder until June 18. Amy Goodwin...
BioCentury | Feb 9, 2018
Financial News

mRNA company Moderna raises $500M series G

...$7 billion." Placement agents for the financing were Goldman Sachs, J.P. Morgan and Morgan Stanley. Goodwin...
Items per page:
1 - 10 of 68
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...at BMO Capital Markets, where he was a senior equity research analyst covering biopharma companies. Goodwin...
...life sciences practices as a partner in the law firm’s New York office. Wound joined Goodwin...
BioCentury | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

...and business development at Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN). Wendy Pan told BioCentury she joined Goodwin...
...Inc. (NASDAQ:AMGN) acquired in 2014. BioCentury Staff Arch Oncology Inc. Cerevel Therapeutics LLC Intellia Therapeutics Inc. Medeor Therapeutics Inc. RedHill Biopharma Ltd. Goodwin...
BioCentury | Dec 21, 2018
Company News

CFIUS gives Novartis, Endocyte deal a pass -- for now

...CFIUS left the door open to potentially revisiting the deal down the road, according to Goodwin...
BioCentury | Dec 19, 2018
Company News

CFIUS gives Novartis, Endocyte deal a pass -- for now

...CFIUS left the door open to potentially revisiting the deal down the road, according to Goodwin...
BioCentury | Dec 17, 2018
Politics & Policy

ACA ruling threatens biosimilars provisions

...entire law as an unconstitutional overreach. An appeal is likely. Elaine Blais, a partner at Goodwin...
BioCentury | Oct 25, 2018
Distillery Therapeutics

Infectious disease

...New York, N.Y. email: elizabeth.campbell@rockefeller.edu CONTACT: Sean F. Brady, same affiliation as above email: sbrady@rockefeller.edu Amy Goodwin Rockefeller...
BioCentury | Oct 19, 2018
Politics, Policy & Law

CFIUS waiting game

...is emerging biotech.” Stephen Paul Mahinka, Morgan Lewis According to two attorneys, Richard Matheny at Goodwin...
...“The costs for preparing a notice or a declaration would not be trivial.” Richard Matheny, Goodwin...
BioCentury | Oct 18, 2018
Distillery Therapeutics

Cancer

...Medicine, Stanford, Calif. email: suzanakahn@gmail.com CONTACT: Samuel H. Cheshier, same affiliation as above email: samuel.chesire@hsc.utah.edu Amy Goodwin Stanford...
BioCentury | Apr 18, 2018
Politics & Policy

Patients emphasize unmet needs in opioid use disorder meeting

...FDA is accepting public comments on the PFDD for opioid use disorder until June 18. Amy Goodwin...
BioCentury | Feb 9, 2018
Financial News

mRNA company Moderna raises $500M series G

...$7 billion." Placement agents for the financing were Goldman Sachs, J.P. Morgan and Morgan Stanley. Goodwin...
Items per page:
1 - 10 of 68